Log in

Dare Bioscience Stock Price, News & Analysis (NASDAQ:DARE)

$0.72
0.00 (0.00 %)
(As of 10/14/2019 02:00 AM ET)
Today's Range
$0.72
Now: $0.72
$0.75
50-Day Range
$0.72
MA: $0.79
$0.87
52-Week Range
$0.60
Now: $0.72
$3.25
Volume58,686 shs
Average Volume50,543 shs
Market Capitalization$12.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.91
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DARE
CUSIPN/A
Phone858-926-7655

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.59 per share

Profitability

Net Income$-16,740,000.00

Miscellaneous

Employees5
Market Cap$12.05 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.


Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions

What is Dare Bioscience's stock symbol?

Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."

How were Dare Bioscience's earnings last quarter?

Dare Bioscience Inc (NASDAQ:DARE) announced its earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.09. View Dare Bioscience's Earnings History.

When is Dare Bioscience's next earnings date?

Dare Bioscience is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Dare Bioscience.

What price target have analysts set for DARE?

2 Wall Street analysts have issued 12-month price objectives for Dare Bioscience's stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Dare Bioscience's share price to reach $3.00 in the next year. This suggests a possible upside of 315.4% from the stock's current price. View Analyst Price Targets for Dare Bioscience.

What is the consensus analysts' recommendation for Dare Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dare Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dare Bioscience.

Has Dare Bioscience been receiving favorable news coverage?

Press coverage about DARE stock has trended negative on Monday, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dare Bioscience earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Dare Bioscience.

Are investors shorting Dare Bioscience?

Dare Bioscience saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 621,700 shares, a decline of 12.6% from the August 30th total of 711,600 shares. Based on an average trading volume of 113,300 shares, the days-to-cover ratio is currently 5.5 days. Approximately 4.6% of the company's stock are short sold. View Dare Bioscience's Current Options Chain.

Who are some of Dare Bioscience's key competitors?

What other stocks do shareholders of Dare Bioscience own?

Who are Dare Bioscience's key executives?

Dare Bioscience's management team includes the folowing people:
  • Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 52)
  • Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 60)
  • Mr. Mark Walters, VP of Operations (Age 64)
  • Ms. MarDee J. Haring-Layton, VP of Accounting & Fin. (Age 43)
  • Dr. David Friend, Chief Scientific Officer

How do I buy shares of Dare Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dare Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $0.72.

How big of a company is Dare Bioscience?

Dare Bioscience has a market capitalization of $12.05 million. The biotechnology company earns $-16,740,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe.View Additional Information About Dare Bioscience.

What is Dare Bioscience's official website?

The official website for Dare Bioscience is http://www.darebioscience.com/.

How can I contact Dare Bioscience?

Dare Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]


MarketBeat Community Rating for Dare Bioscience (NASDAQ DARE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  275 (Thanks for Voting!)
Underperform Votes:  199 (Thanks for Voting!)
Total Votes:  474
MarketBeat's community ratings are surveys of what our community members think about Dare Bioscience and other stocks. Vote "Outperform" if you believe DARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel